Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Atavistik Bio, Inc
Pfizer
Eli Lilly and Company
DL Analytics
Corcept Therapeutics
Marengo Therapeutics, Inc.
Novartis
Revolution Medicines, Inc.
Karyopharm Therapeutics Inc
Mabwell (Shanghai) Bioscience Co., Ltd.
Revolution Medicines, Inc.
Advaxis, Inc.
Hoffmann-La Roche
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Eli Lilly and Company